Amneal Pharma

Compare

568 Followers

AMRX Stock Chart & Stats

$10.24

$0.07(0.89%)

At close: Jan 08 4:00 PM EST

$10.24

$0.07(0.89%)

Day’s Range― - ―

52-Week Range$6.69 - $10.68

Previous CloseN/A

Volume380.73K

Average Volume (3M)1.57M

Market Cap

$3.40B

Enterprise Value$5.17B

Total Cash (Recent Filing)$201.25M

Total Debt (Recent Filing)$119.22M

Price to Earnings (P/E)751.4

Beta0.95

Next Earnings

Mar 04, 2026

EPS Estimate

0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.17

Shares Outstanding314,079,300

10 Day Avg. Volume1,199,751

30 Day Avg. Volume1,572,441

Financial Highlights & Ratios

PEG Ratio1.00

Price to Book (P/B)-22.40

Price to Sales (P/S)0.88

P/FCF Ratio10.06

Enterprise Value/Market Cap1.52

Enterprise Value/Revenue1.76

Enterprise Value/Gross Profit4.80

Enterprise Value/Ebitda11.66

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Business PositioningAMRX's generics business is increasingly well-positioned with a portfolio more focused on complex products and biosimilars, supporting sustainable growth over the next several years.

Product LaunchWith the Crexont launch off to a solid start and continued momentum elsewhere across the portfolio, analyst upgrades AMRX to OW from N.

Bears Say

Market CautionThere is a more mixed view on Crexont and more caution than the Street on overall Gx fundamentals longer-term.

Amneal Pharmaceuticals News

Amneal Pharmaceuticals price target raised to $13 from $11 at Piper Sandler

Piper Sandler raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $13 from $11 and keeps an...

2d ago

AMRX

Amneal Pharmaceuticals reports Q3 adjusted EPS 17c, consensus 14c

Reports Q3 revenue $785M, consensus $773.81M. “Amneal delivered another strong quarter and updated our 2025 outlook, underscoring the...

3d ago

AMRX

Amneal Pharmaceuticals raises 2025 adjusted EPS view to 75c-80c from 70c-75c

2025 EPS consensus 76c. Still sees 2025 revenue $3.0B-$3.1B, consensus $3.01B. Published first on TheFly – the ultimate...

3d ago

AMRX

Amneal gets FDA approval for beclomethasone dipropionate HFA inhalation aerosol

Amneal Pharmaceuticals (AMRX) announced that the FDA has tentatively approved the company’s abbreviated new drug application for beclomethasone...

4d ago

AMRX

Amneal Pharmaceuticals announces U.S. commercial launch of Brekiya injection

Amneal Pharmaceuticals (AMRX) announced the U.S. commercial launch of Brekiya injection, the first and only ready-to-use dihydroergotamine, DHE,...

6d ago

AMRX

Amneal Pharmaceuticals Reports Strong Q3 Growth Amid Challenges

Amneal Pharma (($AMRX)) has held its Q3 earnings call. Read on for the main highlights of the call....

2d ago

AMRX

Amneal Pharmaceuticals Reports Strong Q3 2025 Results

Amneal Pharma ( ($AMRX) ) has released its Q3 earnings. Here is a breakdown of the information Amneal...

2d ago

AMRX

Amneal Pharmaceuticals Reports Strong Q3 2025 Results

The latest update is out from Amneal Pharmaceuticals ( ($AMRX) ). Amneal Pharmaceuticals reported its financial results for...

3d ago

AMRX

Mycophenolate Pregnancy Registry: Key Insights for Investors

Amneal Pharma (($AMRX)), Sandoz Group Ltd (($SDZXF)), Alkem Laboratories Ltd. (($IN:ALKEM)), Concord Biotech Ltd. (($IN:CONCORDBIO)) announced an update...

6d ago

AMRX

Amneal Pharma’s CREXONT Study: A Potential Game-Changer for Parkinson’s Treatment?

Amneal Pharma (($AMRX)) announced an update on their ongoing clinical study. Amneal Pharmaceuticals, in collaboration with Impax Laboratories,...

6d ago

AMRX

Amneal treatment of known or suspected cyanide poisoning granted orphan status

Amneal EU was granted FDA orphan designation for hydroxocobalamin as a treatment of known or suspected cyanide poisoning,...

1M ago

AMRX

Amneal Pharmaceuticals announces submission of BLA to U.S. FDA for XOLAIR

Amneal Pharmaceuticals (AMRX) announced the submission of a Biologics License Application, BLA, to the U.S. Food and Drug...

1M ago

AMRX

Amneal Pharmaceuticals Positioned for Significant Growth with Strong Product Momentum and Strategic Advantages

J.P. Morgan analyst Chris Schott has maintained their bullish stance on AMRX stock, giving a Buy rating yesterday....

1M ago

AMRX

Amneal Pharmaceuticals receives FDA approval for bimatoprost ophthalmic solution

Amneal Pharmaceuticals (AMRX) announced that the U.S. Food and Drug Administration has approved the Company’s Abbreviated New Drug...

1M ago

AMRX

AMRX FAQ

What was Amneal Pharma’s price range in the past 12 months?

Amneal Pharma lowest stock price was $6.68 and its highest was $10.68 in the past 12 months.

What is Amneal Pharma’s market cap?

Amneal Pharma’s market cap is $3.40B.

When is Amneal Pharma’s upcoming earnings report date?

Amneal Pharma’s upcoming earnings report date is Mar 04, 2026 which is in 122 days.

How were Amneal Pharma’s earnings last quarter?

Amneal Pharma released its earnings results on Oct 30, 2025. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.138 by $0.032.

Is Amneal Pharma overvalued?

According to Wall Street analysts Amneal Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Amneal Pharma pay dividends?

Amneal Pharma does not currently pay dividends.

What is Amneal Pharma’s EPS estimate?

Amneal Pharma’s EPS estimate is 0.19.

How many shares outstanding does Amneal Pharma have?

Amneal Pharma has 314,079,300 shares outstanding.

What happened to Amneal Pharma’s price movement after its last earnings report?

Amneal Pharma reported an EPS of $0.17 in its last earnings report, beating expectations of $0.138. Following the earnings report the stock price went down -4.123%.

Which hedge fund is a major shareholder of Amneal Pharma?

Currently, no hedge funds are holding shares in AMRX

Amneal Pharmaceuticals Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-2.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Amneal Pharma

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company based in the United States that specializes in the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The company operates primarily in the prescription drug market and focuses on various therapeutic areas, including central nervous system, infectious disease, endocrinology, and pain management. Amneal's portfolio includes a wide range of generic medications, as well as proprietary branded products, positioning it as a significant player in the pharmaceutical industry.

Amneal Pharmaceuticals (AMRX) Earnings & Revenues

Historic Earnings Reports

AMRX Company Deck

AMRX Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Amneal Pharmaceuticals demonstrated strong financial performance with growth across key segments and raised guidance, though faced challenges with gross margins and potential uncertainties in partnerships.View all AMRX earnings summaries

AMRX Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","11":"$11","7.25":"$7.25","8.5":"$8.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,7.25,8.5,9.75,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.58,9.612307692307692,9.644615384615385,9.676923076923076,9.70923076923077,9.741538461538461,9.773846153846154,9.806153846153846,9.838461538461539,9.87076923076923,9.903076923076924,9.935384615384615,9.967692307692309,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.58,8.843076923076923,8.106153846153846,7.36923076923077,6.632307692307693,5.895384615384616,5.158461538461538,4.421538461538462,3.684615384615385,2.947692307692308,2.2107692307692313,1.4738461538461536,0.7369230769230768,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.58,9.612307692307692,9.644615384615385,9.676923076923076,9.70923076923077,9.741538461538461,9.773846153846154,9.806153846153846,9.838461538461539,9.87076923076923,9.903076923076924,9.935384615384615,9.967692307692309,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.66,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.7,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.49,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.26,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.67,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.42,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >